The Biotech Industry

The Structure of the Biotech Industry

The biotech industry has a distinct layered structure. Big Pharma (Pfizer, Roche, Novartis, J&J, Merck, AbbVie, Sanofi, AstraZeneca) have annual revenues of tens of billions and significant biotech capabilities acquired through internal development and M&A. Mid-sized biotech (Moderna, Regeneron, Vertex, Biogen, Gilead, Alnylam, Illumina) are large enough to be independent but smaller than Big Pharma — often founded around a specific platform technology like mRNA, antibody discovery, or gene editing.

Small biotech startups — thousands of companies, usually founded by academics and VCs around specific scientific breakthroughs. Most have no products on the market. By some estimates, fewer than 10% of biotech startups produce a commercial product. Service and tools companies (Thermo Fisher, Danaher, Lonza, Charles River) are often more profitable than therapeutic companies because they serve the whole industry regardless of which specific drugs succeed.

The structure is dynamic. Small startups get acquired by mid-sized companies; mid-sized companies get acquired by Big Pharma. Occasionally mid-sized biotech companies grow to become Big Pharma equivalents — Gilead, Amgen, Vertex, and Regeneron have all made this transition over the past decade.

Venture Capital and Funding the Pipeline

Bringing a single drug to market costs roughly $1–2 billion and takes 10–15 years. Seed and angel funding ($100K–$5M) validates scientific concepts. Series A through later rounds advance progressively — Series A for early preclinical, Series B–D for clinical trials. Total private funding before IPO can reach $200M–$1B.

Major biotech VCs: Flagship Pioneering (founded Moderna), ARCH Venture Partners, OrbiMed, Third Rock Ventures, Atlas Venture, F-Prime Capital. These firms employ scientific staff with deep domain expertise. Partnerships and licensing with larger pharma companies provide upfront payments, milestone payments, and royalties. M&A: AbbVie acquired Allergan for $63B; Pfizer acquired Seagen for $43B.

Government funding — NIH grants (~$45B annually), NSF, BARDA contracts — provides substantial early-stage research support. The biotech financing system is fragile: investor sentiment changes rapidly. Many companies that looked promising in 2020–2021 closed or were heavily restructured by 2023–2024. Career stability in biotech is consequently lower than in many other technical industries.

Intellectual Property: Patents, Trade Secrets, and Bayh-Dole

The biotech business model rests on IP protection. Biotech patents cover: compositions of matter (specific molecules, antibodies, cell lines), methods of use (using compound X to treat disease Y), methods of production, and devices. Patents last 20 years from filing; the Hatch-Waxman Act provides up to 5 years of extension for regulatory delays.

Patent thickets: many biotech products are covered by dozens or hundreds of overlapping patents. CRISPR commercialization is the famous example — the landscape is so complex that companies pursuing CRISPR therapies must license from multiple competing patent holders. Trade secrets — manufacturing processes, cell lines, proprietary algorithms — are kept confidential rather than disclosed in patents. Potentially perpetual protection, but not protected against independent discovery.

The Bayh-Dole Act (1980) allowed universities to retain patent rights to inventions made with federal funding. Before it, federally funded inventions were generally placed in the public domain. After it, universities could patent academic inventions and license them to companies — including startup companies founded specifically to commercialize academic research. Critics argue that publicly funded inventions then sold back to the public at high prices represent a problematic public-private value transfer.

Drug Development Economics and Careers

The drug development funnel is famously leaky. For every 5,000–10,000 compounds entering preclinical development, roughly 5 enter clinical trials, and only about 1 eventually reaches approval. Most drugs fail in clinical trials. Even at Phase III, failure rates are high — especially for cancer and CNS drugs. The $1–2 billion average cost includes all the failures.

Career paths in biotech span a wide range: research associate (BS/MS entry-level), research scientist (PhD), clinical research associate (CRA), regulatory affairs specialist, medical affairs (MD), business development, IP/biotech law, venture capital (often PhD + MBA), and computational/data science roles that have grown enormously with the rise of genomics and AI-driven drug discovery.

Multiple entry points exist for different skill combinations. What matters more than the specific degree is deep domain knowledge combined with the ability to communicate across disciplines — scientists who understand business, lawyers who understand the science, business people who understand the regulatory landscape. The industry is interdisciplinary in practice even when it doesn't always advertise that way.

Wait, Actually…

The most successful biotech investor of all time isn't a venture capitalist or a Wall Street firm. It's the United States National Institutes of Health.

NIH provides approximately $45 billion annually in research funding. A 2018 study in PNAS found that over 90% of the drugs approved between 2010 and 2016 had received some NIH research funding before approval. The economic return is enormous — pharmaceutical revenues exceed $1 trillion globally — but the returns flow primarily to private companies and shareholders, not back to taxpayers. And then the same drugs are sold back to taxpayers through Medicare and Medicaid at prices set by the private companies.

Proposed reforms include reasonable pricing clauses in NIH grants, march-in rights under Bayh-Dole (theoretically allowing the government to license patents to others if products aren't reasonably available — almost never used), and public manufacturing options. None have gained substantial political traction. The current system — public funding for foundational research, private commercialization, market-based pricing — is deeply entrenched. Whether it's the right balance is one of the larger unresolved questions in biotech and pharmaceutical policy.

---